drugset / Trial / NCT05431595
Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy
Phase 2/3
Recruiting
42 enrolled
M.D. Anderson Cancer Center
Cancer Prevention Research Institute of Texas · collab
RandomizedSingle-groupOpen-labelSupportive care
Summary
To examine the effects of haloperidol, chlorpromazine, valproic acid and placebo, in conjunction with standardized non-pharmacologic interventions, in the first line treatment of agitated delirium in hospitalized patients with cancer. This double-blind, randomized clinical trial aims to provide evidence on various therapeutic options for palliating delirium, thereby reducing delirium-related distress and ultimately alleviating suffering.
Timeline
- Start
- 2022-07-19
- Primary completion
- 2027-02-02
- Completion
- 2027-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Chlorpromazine | Small molecule | — | Intravenous |
| Subject | Haloperidol | Other / unclassified | — | Intravenous |
| Subject | Valproate | Small molecule | — | Intravenous |